Status:
UNKNOWN
Evaluation of Clinical Treatment of Multiple Myeloma Based on Multi-omics
Lead Sponsor:
Beijing Chao Yang Hospital
Conditions:
Multiple Myeloma
Bortezomib
Eligibility:
All Genders
18-100 years
Brief Summary
With the emergence of new drugs, the short-term survival rate of multiple myeloma has been significantly increased. However, in clinical treatment, doctors found that different patients may present di...
Eligibility Criteria
Inclusion
- exposure group:
- Patients diagnosed with multiple myeloma.
- Patients with fluorescence in situ hybridization report results, and try to obtain genetic diagnosis results.
- healthy control group: Patients diagnosed without multiple myeloma, such as other chronic diseases or blood tumors.
Exclusion
- Patients without complete clinical information.
- Patients with malignant epidemic diseases.
- Patients with alcohol abuse or special dietary habit .
- Patients with digestive system diseases, such as inflammatory bowel disease, intestinal infectious disease or other diseases that may affect digestive system function.
- Patients with a history of gastrointestinal operation.
- Patients with severe renal insufficiency without regular dialysis.
- Patients with other possibilities who has severe liver or kidney function injury without intervention.
Key Trial Info
Start Date :
May 16 2019
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 1 2023
Estimated Enrollment :
350 Patients enrolled
Trial Details
Trial ID
NCT04678089
Start Date
May 16 2019
End Date
December 1 2023
Last Update
April 28 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Beijng Chao Yang Hospital
Beijing, China, 100020